InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue, net | $172K+33.3% | $129K-98.7% | $9.8M-18.4% | $12.0M+175.8% | $4.3M |
| Cost of product revenue | $3.8M+93.0% | $2.0M-4.0% | $2.0M+0.9% | $2.0M-13.5% | $2.3M |
| Research and development | $25.0M+50.9% | $16.5M-11.0% | $18.6M+5.4% | $17.6M+17.0% | $15.1M |
| Sales and marketing | $9.2M+20.1% | $7.7M+19.1% | $6.5M-26.9% | $8.8M-0.6% | $8.9M |
| General and administrative | $18.6M+14.2% | $16.3M-1.5% | $16.6M-7.2% | $17.9M+4.5% | $17.1M |
| Impairment loss on indefinite-lived intangible assets | $800K | — | — | — | — |
| Total operating expenses | $57.4M+35.0% | $42.5M-3.5% | $44.1M-5.0% | $46.4M+2.9% | $45.0M |
| Loss from operations | -$45.9M-48.9% | -$30.8M+10.1% | -$34.3M+0.4% | -$34.4M+15.5% | -$40.7M |
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | -$6.3M+33.9% | -$9.5M-85.1% | -$5.1M-25525.0% | -$20K+99.0% | -$2.0M |
| Gain (loss) on extinguishment of debt | -$1.8M-244.5% | $1.2M-66.3% | $3.7M+269.0% | -$2.2M-190.4% | -$753K |
| Interest income (expense) | -$67K+71.0% | -$231K+96.4% | -$6.4M+49.8% | -$12.7M-51.1% | -$8.4M |
| Other income (expense) | $43K-15.7% | $51K-74.5% | $200K-78.9% | $950K+224.2% | -$765K |
| Loss before income tax expense | -$54.0M-37.6% | -$39.3M+6.3% | -$41.9M+13.4% | -$48.4M+8.0% | -$52.6M |
| Income tax expense | $0 | $0 | $0 | — | $0 |
| Net loss | -$54.0M-37.6% | -$39.3M+6.3% | -$41.9M+13.4% | -$48.4M+8.0% | -$52.6M |
| Net loss attributable to noncontrolling interest | -$563K+25.8% | -$759K-26.3% | -$601K+36.1% | -$941K-18720.0% | -$5K |
| Deemed dividend to preferred stockholders | -$141K | $0 | — | — | -$130K |
| Net loss attributable to common stockholders | -$53.6M-39.2% | -$38.5M+6.8% | -$41.3M+13.0% | -$47.5M+9.8% | -$52.6M |
| Net loss per share, basic | -$22.97+82.4% | -$130.69+100.0% | -$2.7M-7302.3% | -$36K-40911.1% | -$88.22 |
| Net loss per share, diluted | -$22.97+82.4% | -$130.69+100.0% | -$2.7M-7302.3% | -$36K-40911.1% | -$88.22 |
| Weighted-average common stock outstanding, basic | $2.3M+691.9% | $295K-98.1% | $15.4M-98.8% | $1.31B+219896.7% | $596K |
| Weighted-average common stock outstanding, diluted | $2.3M+691.9% | $295K-98.1% | $15.4M-98.8% | $1.31B+219896.7% | $596K |
| Product revenue, net | |||||
| License revenue | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health (JAGX) Q3 2025 Earnings Transcript